Literature DB >> 15146227

Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study.

Lois Almadrones1, Debroah B McGuire, Janet Ruth Walczak, Colleen M Florio, Chunqiao Tian.   

Abstract

PURPOSE/
OBJECTIVES: To evaluate the psychometric properties of two adapted scales, one for functional status and one for peripheral neuropathy secondary to neurotoxic chemotherapy.
DESIGN: Repeated measures methodologic design conducted within a Gynecologic Oncology Group (GOG) phase III clinical trial that randomly assigned patients with advanced epithelial ovarian cancer to cisplatin and cyclophosphamide or cisplatin and paclitaxel.
SETTING: 8 GOG institutions participating in the GOG clinical trial. SAMPLE: 88 evaluable outpatients enrolled in the GOG clinical trial. Sample size at time 1 (T1) was 88 patients and at time 2 (T2) was 67 patients.
METHODS: All scales were administered at T1 (prior to initiation of chemotherapy) and T2 (after six cycles of chemotherapy but prior to second-look laparotomy). Internal consistency reliability, criterion validity, and construct validity were evaluated, and clinical application was explored. MAIN RESEARCH VARIABLES: Self-reported peripheral neuropathy and functional status (comprised of physical function and role function subscales), the GOG performance status scale, and the GOG toxicity criteria.
FINDINGS: Reliability coefficients at T1 were physical function = 0.83, role function = 0.96, and peripheral neuropathy = 0.91; at T2, they were physical function = 0.83, role function = 0.92, and peripheral neuropathy = 0.89. At T1, physical function and role function correlated positively with performance status. Peripheral neuropathy correlated positively with GOG toxicity criteria used at T2. Principal component factor analysis suggested that the functional status scale had a two-factor structure with factors representing general and specific mobility and that the peripheral neuropathy scale also had a two-factor structure with factors representing foot and hand neuropathy.
CONCLUSIONS: The physical function, role function, and peripheral neuropathy scales have internal consistency, reliability, criterion validity, and construct validity. However, revision of the scales should address modification of specific questions and consider increasing the Likert scale from a four-point to a five- or seven-point scale to enhance clinical sensitivity and application. IMPLICATIONS FOR NURSING: With minor modifications, these scales should be useful in assessing physical function, role function, and peripheral neuropathy in patients who receive agents that may cause peripheral neuropathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15146227     DOI: 10.1188/04.ONF.615-623

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  19 in total

1.  Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors.

Authors:  Cindy Tofthagen; Kristine A Donovan; Mary Ann Morgan; David Shibata; Yating Yeh
Journal:  Support Care Cancer       Date:  2013-08-01       Impact factor: 3.603

Review 2.  Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey.

Authors:  J Matt McCrary; David Goldstein; Frances Boyle; Keith Cox; Peter Grimison; Matthew C Kiernan; Arun V Krishnan; Craig R Lewis; Kate Webber; Sally Baron-Hay; Lisa Horvath; Susanna B Park
Journal:  Support Care Cancer       Date:  2017-06-07       Impact factor: 3.603

3.  Pain, neuropathic symptoms, and physical and mental well-being in persons with cancer.

Authors:  Cindy S Tofthagen; Susan C McMillan
Journal:  Cancer Nurs       Date:  2010 Nov-Dec       Impact factor: 2.592

4.  Nursing research in the Gynecologic Oncology Group.

Authors:  Heidi S Donovan; Susan Nolte; Robert P Edwards; Lari Wenzel
Journal:  Semin Oncol Nurs       Date:  2013-12-19       Impact factor: 2.315

5.  Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale.

Authors:  Tito R Mendoza; Xin Shelley Wang; Loretta A Williams; Qiuling Shi; Elisabeth G Vichaya; Patrick M Dougherty; Sheeba K Thomas; Emre Yucel; Christel C Bastida; Jeanie F Woodruff; Charles S Cleeland
Journal:  J Pain       Date:  2015-07-22       Impact factor: 5.820

6.  The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep disturbance in cancer patients.

Authors:  J S Hong; J Tian; L H Wu
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

7.  Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601.

Authors:  E M L Smith; H Pang; C Ye; C Cirrincione; S Fleishman; E D Paskett; T Ahles; L R Bressler; N Le-Lindqwister; C E Fadul; C Loprinzi; C L Shapiro
Journal:  Eur J Cancer Care (Engl)       Date:  2015-11-25       Impact factor: 2.520

8.  Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure.

Authors:  C M L Driessen; K M E de Kleine-Bolt; A J J M Vingerhoets; F Mols; G Vreugdenhil
Journal:  Support Care Cancer       Date:  2011-12-09       Impact factor: 3.603

9.  Multiple myeloma and diabetes.

Authors:  Zeinab A Issa; Mira S Zantout; Sami T Azar
Journal:  ISRN Endocrinol       Date:  2011-11-17

10.  A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles.

Authors:  Bengt Sorbe; Marianne Graflund; Lisa Nygren; György Horvath
Journal:  Oncol Lett       Date:  2013-01-22       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.